Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus calmette-guérin purified protein derivative
- Development stage
- Phase 1
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
bacillus calmette-guérin purified protein derivative is a diagnostic reagent developed by Anhui Zhifei Longcom Biopharmaceutical for the detection of tuberculosis infection and the evaluation of BCG vaccination efficacy. The product consists of a purified protein fraction derived from the Bacillus Calmette-Guérin (BCG) strain of Mycobacterium bovis. Administered via intradermal injection, it functions by eliciting a delayed-type hypersensitivity (DTH) response in individuals whose immune systems have been sensitized to mycobacterial antigens through prior infection or vaccination. The resulting skin induration, measured 48 to 72 hours after administration, serves as a marker of cell-mediated immunity. This reagent is particularly useful in clinical protocols for screening populations for tuberculosis and monitoring the success of BCG immunization programs.
- Brand names
- Purified Tuberculin
- Other names
- BCG-PPDTuberculin purified protein derivativePPDBCG purified protein derivative
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on bacillus calmette-guérin purified protein derivative.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus calmette-guérin purified protein derivative.